Global Newborn Screening Market

Newborn Screening Market Size, Share, Growth Analysis, By Product (Consumables, Instruments), By Technology (Tandem Mass Spectrometry, Pulse Oximetry), By Test Type (Dry Blood Spot Test, CCHD), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35E2050 | Region: Global | Published Date: November, 2024
Pages: 177 | Tables: 89 | Figures: 71

Newborn Screening Market Competitive Landscape

The newborn screening market is highly competitive, dominated by the main manufacturers Abbott, Roche, and PerkinElmer, which have been at the forefront with wide screening panels and new modern methodologies of testing. Expanding due to increased awareness of genetic disorders, support programs from the government are emerging for early identification. New companies are trying digital health integration and rapid testing methods. Two major challenges are reimbursement rules and regulatory compliance. Congenital disorders are becoming increasingly common and drive the demand for more such drugs, indicating continued investment in R&D and strategic alliances with other big pharma companies.

Top Player’s Company Profiles

  • Masimo Corp. 
  • Covidien Plc 
  • AB Sciex LLC 
  • Natus Medical Inc. 
  • Agilent Technologies Inc. 
  • PerkinElmer Inc. 
  • GE Healthcare 
  • Bio-Rad Laboratories Inc. 
  • Trivitron Healthcare 
  • Medtronic Inc. 
  • Rady Children's Institute for Genomic Medicine 
  • GE Lifesciences 
  • Waters Corporation 
  • Danaher Corporation 
  • Thermo Fisher Scientific Inc. 
  • VIVOSONIC 
  • ZIVAK TECHNOLOGIES 
  • CAMAG 
  • OTODYNAMICS 
  • ZENTECH

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Newborn Screening Market size was valued at USD 1.25 Billion in 2023 and is poised to grow from USD 1.34 Billion in 2024 to USD 2.12 Billion by 2031, growing at a CAGR of 6.8% in the forecast period (2024-2031).

The newborn screening market is highly competitive, dominated by the main manufacturers Abbott, Roche, and PerkinElmer, which have been at the forefront with wide screening panels and new modern methodologies of testing. Expanding due to increased awareness of genetic disorders, support programs from the government are emerging for early identification. New companies are trying digital health integration and rapid testing methods. Two major challenges are reimbursement rules and regulatory compliance. Congenital disorders are becoming increasingly common and drive the demand for more such drugs, indicating continued investment in R&D and strategic alliances with other big pharma companies. 'Masimo Corp. ', 'Covidien Plc ', 'AB Sciex LLC ', 'Natus Medical Inc. ', 'Agilent Technologies Inc. ', 'PerkinElmer Inc. ', 'GE Healthcare ', 'Bio-Rad Laboratories Inc. ', 'Trivitron Healthcare ', 'Medtronic Inc. ', 'Rady Children's Institute for Genomic Medicine ', 'GE Lifesciences ', 'Waters Corporation ', 'Danaher Corporation ', 'Thermo Fisher Scientific Inc. ', 'VIVOSONIC ', 'ZIVAK TECHNOLOGIES ', 'CAMAG ', 'OTODYNAMICS ', 'ZENTECH'

The increasing prevalence of congenital abnormalities is said to be the primary cause for the rising trend of newborn screening. These kinds of congenital anomalies include genetic disorders, hearing impairment, and metabolic disorders. It is crucially important to diagnose such anomalies early because a proper intervention may sharply improve the quality of life and the desired outcome of the treatment for neonates suffering from these conditions. With the advancement of medical technology and an improved understanding of early advantages of diagnosis, the importance of screening programs is rising. As an increased awareness of congenital illnesses grows and more attention has been paid to it in recent years, the use of thorough screening techniques to better protect the health of newborns in their later years by identifying abnormalities before symptoms develop continues to be done with utmost interest.

Advanced Genetic Testing Integration: There is probably no area where innovation in newborn screening has possibly brought about as significant a development as advanced genetic testing. This includes WGS and NGS, which enable the more accurate detection of an increasingly larger group of genetic disorders. These technologies can have more advanced screening through the complex and rare genetic disorders that may not be identified by traditional techniques. As technology advances, more comprehensive panels are now available because the cost of conducting genetic tests will continue to fall. This will enable earlier detection and with greater accuracy genetic abnormalities and improve the outcomes, hence expanding newborn screening programs.

Asia Pacific had the highest share of 32.90% in the newborn screening market. This leadership is due to new growth prospects along with better healthcare services and infrastructure. The demand for newborn screening techniques is a result of a high birth rate, dense population, and rising incidence of congenital disorders in the region. Government programs and spending on healthcare facilities are forecast to push the market further. The Asia Pacific is expected to grow at the fastest rate, followed by countries such as China and India that are setting benchmarks for advanced newborn screening techniques.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Feedback From Our Clients

Global Newborn Screening Market

Report ID: SQMIG35E2050

$5,300
BUY NOW GET FREE SAMPLE